Literature DB >> 1458938

Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside.

N A Halpern1, M Goldberg, C Neely, R N Sladen, J S Goldberg, J Floyd, G Gabrielson, R J Greenstein.   

Abstract

OBJECTIVE: To compare the efficacy and safety of iv nicardipine with sodium nitroprusside in the treatment of postoperative hypertension after both cardiac and noncardiac surgery.
DESIGN: Multicenter, prospective, randomized, open-label study.
SETTING: Six tertiary referral medical centers (recovery rooms and surgical ICUs). PATIENTS: A total of 139 patients with postoperative hypertension: i.v. nicardipine (n = 71), sodium nitroprusside (n = 68). INTERVENTION: Administration of i.v. nicardipine or sodium nitroprusside. MEASUREMENTS: Vital signs (BP, heart rate), hemodynamic variables, medication dosage, total number of dose changes, and time to achieve BP control were recorded. MAIN
RESULTS: Both medications were equally effective in reducing BP in both the cardiac and noncardiac surgical groups. Under the conditions of the study, i.v. nicardipine controlled hypertension more rapidly than sodium nitroprusside (i.v. nicardipine 14.0 +/- 1.0 mins and sodium nitroprusside 30.4 +/- 3.5 mins, p = .0029). The total number of dose changes required to achieve therapeutic BP response was significantly less in the i.v. nicardipine-treated patients (i.v. nicardipine 1.5 +/- 0.2 vs. sodium nitroprusside 5.1 +/- 1.4, p < .05). Adverse effects were observed with both drugs (i.v. nicardipine 7% [5/71] and sodium nitroprusside 18% [12/68] [NS]).
CONCLUSIONS: Intravenous nicardipine is as effective as sodium nitroprusside in the therapy of postoperative hypertension. Specific advantages have been identified. The use of i.v. nicardipine should be considered in the therapy of postoperative hypertension.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458938

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  22 in total

1.  Nicardipine infusion for blood pressure control in patients with subarachnoid hemorrhage.

Authors:  Panayiotis N Varelas; Tamer Abdelhak; Jody Wellwood; Irem Shah; Lotfi Hacein-Bey; Lonni Schultz; Panayiotis Mitsias
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

Review 2.  Intravenous nicardipine: its use in the short-term treatment of hypertension and various other indications.

Authors:  Monique P Curran; Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Sepsis-related hypertensive response: friend or foe?

Authors:  Mohamed Saleh
Journal:  BMJ Case Rep       Date:  2014-05-22

4.  Examining the Use of Sodium Nitroprusside in Coronary Artery Bypass Grafting: Is the Benefit Worth the Cost?

Authors:  Caitlin M Gibson; Sondra Davis; Darien Bradford
Journal:  Hosp Pharm       Date:  2017-07-30

5.  Coarctation of the aorta associated with Dandy-Walker variant.

Authors:  Li Zhou; George K Lui; Rajesh Shenoy; Cynthia C Taub
Journal:  J Cardiovasc Dis Res       Date:  2013-08-20

6.  Intracerebral hemorrhage: clinical overview and pathophysiologic concepts.

Authors:  Fred Rincon; Stephan A Mayer
Journal:  Transl Stroke Res       Date:  2012-04-21       Impact factor: 6.829

7.  Therapeutic Interchange of Clevidipine For Sodium Nitroprusside in Cardiac Surgery.

Authors:  Joseph E Cruz; Zachariah Thomas; David Lee; David M Moskowitz; Jeff Nemeth
Journal:  P T       Date:  2016-10

8.  Antihypertensive treatment of acute cerebral hemorrhage.

Authors: 
Journal:  Crit Care Med       Date:  2010-02       Impact factor: 7.598

Review 9.  Strategies for managing perioperative hypertension.

Authors:  Ronak G Desai; Muhammad Muntazar; Michael E Goldberg
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

Review 10.  Comparative tolerability profile of hypertensive crisis treatments.

Authors:  E Grossman; A N Ironi; F H Messerli
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.